Revance's frown-line injection latest to face regulatory delay after FDA can't hit inspection deadline

Revance will have to wait for an FDA decision on its frown-line injection daxibotulinumtoxinA after the FDA admitted it couldn't inspect the company's Newark, California manufacturing facility on time because of COVID-19 restrictions.